CClinicalTrials.gg
CompletedNCT07487220RIPCUpdated Mar 25, 2026

Non-invasive Remote Ischemic PreConditioning (RIPC) in Free Flaps for Breast Reconstruction

An interventional study of Remote ischemic preconditiong in Ischemia-Reperfusion Injury, Free Flap and Conditioning Therapy, sponsored by Ruhr University of Bochum. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Ruhr University of Bochum · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This prospective randomized clinical study investigates the effects of Remote Ischemic Conditioning (RIC) on tissue perfusion and ischemia-reperfusion injury in patients undergoing free flap reconstruction in reconstructive microsurgery. RIC is a non-invasive conditioning technique using cyclic ischemia and reperfusion applied to an extremity, which may enhance microcirculation and induce tissue protection.

The study aims to evaluate whether preoperative RIC improves postoperative flap perfusion, reduces ischemia-reperfusion- related tissue damage, and enhances clinical outcomes such as flap survival, wound healing, and need for revision surgery. Patients undergoing free flap procedures will be randomized to receive either preoperative RIC (immediate or delayed) or no conditioning.

Additional analyses include continuous postoperative monitoring of microcirculation, histological and molecular assessment of tissue samples, and evaluation of circulating biomarkers associated with tissue protection.

Read the detailed description

Background Free flap reconstruction represents the gold standard for complex soft tissue defects arising from tumor resection, trauma, or chronic wounds. Despite refinements in microsurgical technique and perioperative management, flap-related complications, including partial necrosis, wound healing disorders, and total flap loss, continue to occur at clinically meaningful rates. The underlying pathophysiology involves obligatory ischemia during flap harvest and transfer, followed by reperfusion upon anastomosis completion. This ischemia-reperfusion (I/R) sequence triggers a cascade of oxidative stress, endothelial dysfunction, inflammatory activation, and microcirculatory failure that can ultimately compromise tissue viability.

Current intraoperative strategies to mitigate I/R injury remain limited, and no pharmacological or mechanical intervention has been established as standard of care in this context.

Scientific Rationale for Remote Ischemic Conditioning Remote Ischemic Conditioning (RIC) exploits the endogenous capacity of biological tissue to develop tolerance to ischemic stress when exposed to brief, non-lethal cycles of ischemia and reperfusion at a site distant from the target organ. Originally described in cardiac surgery, RIC has since been investigated across a range of ischemia-sensitive tissues and clinical scenarios. Proposed mechanisms include neuronal and humoral signaling pathways that activate cytoprotective programs, such as upregulation of heat shock proteins, modulation of the RISK (Reperfusion Injury Salvage Kinase) pathway, suppression of mitochondrial permeability transition pore opening, and attenuation of neutrophil-mediated endothelial injury.

Preclinical models of pedicled and free flaps have demonstrated improved perfusion, reduced apoptosis, and enhanced flap survival following RIC. However, these findings have not yet been translated into a prospective randomized clinical trial in reconstructive microsurgery.

Timing of Conditioning: Study Design Rationale A key unresolved question concerns the optimal timing of RIC relative to surgery. Two biologically distinct windows of protection have been described: an immediate window (within approximately 1-2 hours of the conditioning stimulus, mediated largely by post-translational protein modifications) and a delayed window (emerging 12*24 hours later, dependent on de novo protein synthesis and gene expression changes). To address this, the trial incorporates three parallel arms: a non-conditioned control group, an immediately preconditioned group (approximately 1 hour before surgery), and a delayed preconditioned group (12-24 hours preoperatively). This design enables direct comparison of both conditioning windows against each other and against standard care.

In cases where intraoperative findings necessitate unplanned revision surgery, a secondary randomization procedure is pre-specified to evaluate the potential benefit of RIC in the setting of threatened flap perfusion.

Intervention Protocol RIC is applied non-invasively to the upper arm using a standard pneumatic tourniquet. Each conditioning session consists of three alternating cycles of 10-minute ischemia (cuff inflated to approximately 250 mmHg, sufficient to occlude arterial inflow) and 10-minute reperfusion (cuff deflated), for a total session duration of 60 minutes. This protocol is consistent with those used in cardiovascular RIC trials and has a well-characterized safety profile.

Microcirculatory Monitoring Postoperative flap perfusion will be continuously assessed using a multimodal approach combining laser Doppler flowmetry and tissue spectrometry (O2C device or equivalent). These complementary techniques enable real-time, non-invasive quantification of microvascular flow, tissue oxygen saturation, and relative hemoglobin concentration. Measurements will be obtained at standardized time points throughout the first five postoperative days, allowing construction of perfusion trajectories and identification of early signs of compromised microcirculation.

Tissue and Biomarker Analyses Standardized biopsies will be obtained from clinically non-essential portions of the flap at defined intraoperative and early postoperative time points. Samples will undergo histological and immunohistochemical evaluation for markers of ischemic injury, cellular stress responses, inflammatory infiltration, and apoptosis. Parallel molecular analyses will characterize expression of proteins and signaling mediators implicated in I/R injury and cytoprotection.

Serial blood samples will be collected perioperatively to quantify circulating biomarkers, including but not limited to markers of oxidative damage, endothelial activation, and systemic inflammatory response. These analyses serve both to detect systemic correlates of local tissue protection and to identify candidate biomarkers for future use in monitoring RIC efficacy.

Clinical Outcome Assessment In addition to mechanistic endpoints, the trial will capture a comprehensive set of clinical outcomes through postoperative day 5 and beyond, including flap survival rate, incidence and severity of wound healing disorders, requirement for revision surgery or re-anastomosis, and total length of inpatient stay. Adverse events and protocol deviations will be systematically recorded.

Statistical Considerations Sample size estimation is based on the primary perfusion endpoint. Randomization will be performed centrally with stratification for relevant clinical variables. All primary analyses will follow the intention-to-treat principle; per-protocol analyses will be conducted as sensitivity analyses.

Significance If RIC is demonstrated to improve perfusion and reduce I/R injury in this setting, it would offer a compelling adjunct to reconstructive microsurgery: it is non-invasive, requires no specialized pharmacology, adds minimal procedural complexity, and is associated with a favorable safety profile in other surgical disciplines. The results of this trial are expected to inform evidence-based guidelines for perioperative conditioning in free flap surgery and to lay the groundwork for larger multicenter investigations.

02

Conditions studied

  • Ischemia-Reperfusion Injury
  • Free Flap
  • Conditioning Therapy

Keywords

  • ischemia
  • reperfusion
  • free flap
  • Wound Healing
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥ 18 years
  • Patients undergoing free flap reconstruction surgery for reconstruction of body surface defects
  • Treatment at the Department of Plastic Surgery, BG Universitätsklinikum Bergmannsheil Bochum
  • Ability to understand the study procedures
  • Written informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Refusal or inability to provide informed consent
  • Contraindications to regional nerve block or perioperative procedures required for the study
  • Any condition that prevents participation according to investigator judgment
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • No intervention
    No RIPC

    No Remote Ischemic Conditioning (RIC) is administered. Participants receive standard perioperative care and undergo free flap reconstruction according to institutional protocols without any preconditioning intervention.

  • Experimental
    Early RIPC

    Remote Ischemic Conditioning (RIC) is performed 12-24 hours prior to surgery. The intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols.

    Device: Remote ischemic preconditiong

  • Experimental
    Late RIPC

    Remote Ischemic Conditioning (RIC) is performed one hour prior to surgery. The intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols.

    Device: Remote ischemic preconditiong

Interventions

  • DeviceRemote ischemic preconditiong

    The intervention consists of three cycles of ischemia and reperfusion applied to the upper arm using a pneumatic tourniquet. Each cycle includes 10 minutes of ischemia (inflation to approximately 250 mmHg) followed by 10 minutes of reperfusion (deflation). The total duration of the conditioning procedure is 60 minutes. Participants subsequently undergo free flap reconstruction according to standard institutional protocols.

05

What researchers measure

Primary outcomes

  1. Microcirculatory perfusion of free flap tissue measured by Laser-Doppler flowmetry and tissue spectrometry

    Continuous assessment of microcirculatory perfusion parameters of free flap tissue using combined Laser-Doppler flowmetry and tissue spectrometry (O2C system). Parameters include blood flow (BF), tissue oxygen saturation (StO₂), and relative hemoglobin concentration (rHb) measured in the transplanted tissue to evaluate the effect of remote ischemic conditioning on flap perfusion and ischemia-reperfusion injury.

    Time frame: From intraoperative revascularization until postoperative day 5

Secondary outcomes

  1. Incidence of flap tissue necrosis following free flap reconstruction

    Occurrence and extent of partial or complete flap necrosis following free tissue transfer surgery, assessed clinically during the postoperative observation period.

    Time frame: Up to postoperative day 5

  2. Histological markers of vascularization and ischemia-reperfusion injury in flap tissue

    Histological and immunohistochemical analysis of tissue biopsies obtained from the transplanted flap to assess vascularization, cellular damage, inflammatory response, and expression of ischemia-reperfusion related proteins (e.g., HIF1α, VEGF, TNFα, IL-1β). Analyses are performed on intraoperative and postoperative tissue samples to evaluate the biological effects of remote ischemic conditioning.

    Time frame: From intraoperative sampling after revascularization until postoperative day 5-7

06

Study locations

1 site
  • BG University Clinic Bergmannsheil
    Bochum, North Rhine-Westphalia 44789, Germany
07

References and documents

Publications

  • Drysch M, Fiedler A, Schmidt SV, Reinkemeier F, Puscz F, Kurbacher T, Frey UH, Ochsenfarth C, Lehnhardt M, Wallner C, Sogorski A. Systemic downregulation of EV-associated MiRNAs following remote ischemic preconditioning. Sci Rep. 2025 Dec 11;15(1):43657. doi: 10.1038/s41598-025-31356-9. PubMed 41381697 ↗
  • Drysch M, Fiedler A, Kurbacher T, Schmidt SV, Reinkemeier F, Puscz F, Becerikli M, Fueth M, Weskamp P, Lehnhardt M, Wallner C, Sogorski A. Ischemia-Reperfusion Injury in Free Flaps: Molecular Mechanisms and Protective Effects of Remote Ischemic Preconditioning. J Cell Mol Med. 2025 Aug;29(15):e70739. doi: 10.1111/jcmm.70739. PubMed 40771071 ↗

Individual participant data

Plan to share: No — Individual participant data collected in this study will not be made publicly available. All study data will be pseudonymized and stored on secure institutional servers with access restricted to authorized study personnel. Data are collected as part of a single-center clinical study and contain potentially identifiable clinical information. Aggregated results may be published in scientific journals, but individual-level data will not be shared outside the study team in order to protect participant confidentiality.

08

Registry details

Key details

Study ID
NCT07487220
Lead sponsor
Ruhr University of Bochum
Responsible party
ALEXANDER FIEDLER (Resident Physician, Department of Plastic, Reconstructive and Burn Surgery, Ruhr University of Bochum) — Principal investigator
First posted
Mar 23, 2026
Start date
Apr 1, 2021
Primary completion
Dec 31, 2022
Completion
Dec 31, 2023
Last update
Mar 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion